BERWYN, Pa.–(BUSINESS WIRE)–AscellaHealth, a global healthcare and specialty pharmacy (SP) solutions company, today launches a new brand identity that positions its comprehensive suite of services for the specialty pharmacy industry, namely patients, life sciences manufacturers, payers and providers, under the overarching AscellaHealth name, effective immediately. This refreshed brand architecture strengthens a global market message that reflects the focus of Optime Care, a wholly-owned specialty pharmacy and patient management rare disease company acquired by AscellaHealth in 2021, and Terebellum, its international business consulting subsidiary based in the EU and UK with end-to-end, comprehensive solutions for pharmaceutical manufacturers, payers and other stakeholders, that improve medication access, reduce costs and enhance patient outcomes. Both companies will transition to the AscellaHealth brand identity in their market-facing activities, but each will continue to maintain current business operations, client relationships and dedication to patient-centric care.
“The timing of this transition to a unified brand coincides with our expanded global footprint and the extraordinary growth of AscellaHealth partnerships in the US and international markets, including Europe and the United Kingdom,” says Dea Belazi, president and CEO, AscellaHealth. “With increased large-scale attention on rare diseases and complex conditions as well as the need for customized, tech-enabled solutions that empower pharmaceutical manufacturers to successfully launch specialty drugs and cell and gene therapies, AscellaHealth is truly meeting the needs of specialty and rare disease patients worldwide and proactively addressing market challenges. The AscellaHealth name stands for single-minded dedication to these specialty populations who are at the heart of everything we do as an integrated organization with cohesive market solutions.”
Increased AscellaHealth brand equity among patients, life sciences manufacturers, payers and providers will support further product development and streamlined solutions for specialty pharmacy stakeholders worldwide including:
- Pre-Commercialization & Market Access
- International Specialty Pharmacy Fulfillment
- Exclusive Distribution Partnerships & Supply Chain Logistics
- Integrated Co-pay Assistance Programs
- Patient Support & HUB Services
- Unique Financial Pharmaceutical Services for High-Cost Therapies
- Focus on Cell and Gene Therapies
- Consulting Services for European Companies Launching Products in the United States
- Specialty Pharmacy & Medical Benefit Management
- Group Purchasing Services & Drug Rebate Programs
“Consistent and unified branding under the AscellaHealth name reinforces our capabilities for providing unparalleled pharmaceutical programs and services that are customized for every client partner and backed by the expertise of a team with deep experience in treating and managing rare diseases,” continues Belazi. “Our distinctive AscellaHealth name represents innovation and a pro-active approach to implementing go-to-market strategies. Think of our unified brand identity as a single resource for collaborative support throughout the entire product life cycle, from clinical trial and pre-commercialization through product launch, market access, distribution and beyond.”
AscellaHealth will be attending the AXS23 Summit in Las Vegas, April 30 – May 4, 2023.
To schedule a meeting with an executive member of the AscellaHealth team at AXS23, please contact businessdevelopment@ascellahealth.com.
About AscellaHealth LLC
AscellaHealth, a global Healthcare & Specialty Pharmacy solutions organization, serving patients, life sciences manufacturers, payers and providers, offers a comprehensive portfolio of uniquely tailored, tech-enabled services supporting complex, chronic conditions or rare diseases that require specialty medications and/or cell and gene therapies. A recipient of numerous industry awards for innovation, and a NASP Strategic Channel Partner of the Year award winner, AscellaHealth’s best-in-class, patient-centric approach is built upon proprietary technology processes for novel programs and services to support the launch of specialty medications and proactively address multiple challenges, optimize clinical health outcomes, and improve quality of life for this patient population. AscellaHealth brings a rare and special perspective to all stakeholders. Visit www.AscellaHealth.com.
Contacts
Media:
Nicole Dufour
CPR Communications
ndufour@cpronline.com
201.641.1911 x 54
Marketing:
Darcey McDermott, Chief Marketing & Communications Officer
AscellaHealth
darcey.mcdermott@ascellahealth.com
877.389.9040